Perinatal supplementation with thymoquinone improves diabetic complications and T cell immune responses in rat offspring

Cellular Immunology

Volumn 267, Issue 2, 2011, Pages 133-140

  Badr, Gamal ^a,b   Alwasel, Saleh ^a   Ebaid, Hossam ^a   Mohany, Mohamed ^a   Alhazza, Ibrahim ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Assiut University   (Egypt)

Author keywords

Antioxidant; Maternal diabetes; Offspring; T cells

Indexed keywords

GLUCOSE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; STREPTOZOCIN; SUPERANTIGEN; THYMOQUINONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIRTH WEIGHT; CELL HOMING; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; IMMUNE RESPONSE; IMMUNOSTIMULATION; LACTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MACROSOMIA; NEWBORN; NONHUMAN; PERINATAL PERIOD; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROGENY; PROTEIN BLOOD LEVEL; RAT; STREPTOZOCIN DIABETES; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYMOCYTE; THYMUS;

ACTINS; ANIMALS; ANTIOXIDANTS; APOPTOSIS; BENZOQUINONES; BLOOD GLUCOSE; CELL PROLIFERATION; CYTOKINES; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; INTERLEUKIN-2; LITTER SIZE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; PREGNANCY; PREGNANCY IN DIABETICS; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, INBRED STRAINS; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTE SUBSETS;

RATTUS;

EID: 79751525036     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.01.002     Document Type: Article

References (53)

1. Metzger B.E. Summary and recommendations of the third international workshop - conference on gestational diabetes mellitus. Diabetes 1991, 197-201.
2. Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., Quagliaro L., Ceriello A., Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002, 106:2067-2072.
3. Loukovaara M., Leinonen P., Alfthan H., Stenman U., Andersson S., Teramo K. Fetal hypoxia is associated with elevated cord serum C-reactive protein levels in diabetic pregnancies. Biol. Neonate 2004, 85:237-242.
4. Allan S.M., Rothwell N.J. Cytokines and acute neurodegeneration. Nat. Rev. Neurosci. 2001, 2:734-744.
5. Wilson K.C., Center D.M., Cruikshank W.W., Zhang Y. Binding of HTLV-1 tax oncoprotein to the precursor of interleukin-16, a T-cell PDZ domain-containing protein. Virology 2003, 306:60-67.
6. Chiesa C., Pellegrini G., De Luca T., Assumma M., Signore F., Pacifco L. Umbilical cord interleukin 6 levels are elevated in term neonatres with perinatal asphyxia. Eur. J. Clin. Invest. 2003, 33:352-358.
7. Silveira R.C., Procianoy R.S. Interleukin-6 and tumor necrosis factoralpha levels in plasma and cerebrospinal fluid of term newborn infants with hypoxic-ischemic encephalopathy. J. Pediatr. 2003, 143:625-629.
8. Kowalski J., Blada P., Kucia K., Madej A., Herman Z. Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factoralpha from monocytes in schizophrenia. Schizophr. Res. 2001, 50:169-175.
9. Zalcman S., Green-Johnson J.M., Murray L., Nance D.M., Dyck D., Anisman H., Greenberg A.H. Cytokine-specific central monoamine alterations induces by IL-1 -2 and -6. Brain Res. 1994, 643:40-49.
10. Merrill J.E. Tumor necrosis factor alpha interleukin-1 and related cytokines in brain development: normal and pathological. Dev. Neurosci. 1992, 14:1-10.
11. Mehler M.F., Kessler J.A. Hematolymphopoeitic and inflammatory cytokines in neural development. Trends Neurosci. 1997, 20:357-365.
12. Saliba E., Henrot E. Inflammatory mediators and neonatal brain damage. Biol. Neonate 2001, 79:224-227.
13. West I.C. Radicals and oxidative stress in diabetes. Diabet. Med. 2000, 17:171-180.
14. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15:287-303.
15. Biri A., Onan A., Devrim E., Babacan F., Kavutcu M. Oxidant status in maternal and cord plasma and placental tissue in gestational diabetes. Placenta 2006, 27:327-332.
16. Allen R.G., Venkatraj V.S. Oxidants and antioxidants in development and differentiation. J. Nutr. 1992, 122:631-635.
17. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 1996, 19:1-17.
18. Ali B.H., Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother. Res. 2003, 17(4):299-305.
19. Hajhashemi V., Ghannadi A., Jafarabadi H. Black cumin seed essential oil, as a potent analgesic and antiinflammatory drug. Phytother. Res. 2004, 18(3):195-199.
20. Xuan N.T., Shumilina E., Qadri S.M., Götz F., Lang F. Effect of thymoquinone on mouse dendritic cells. Cell Physiol. Biochem. 2010, 25(2-3):307-314.
21. Kanter M. Effects of Nigella sativa and its major constituent, thymoquinone on sciatic nerves in experimental diabetic neuropathy. Neurochem. Res. 2008, 33(1):87-96.
22. Fararh K.M., Shimizu Y., Shiina T., Nikami H., Ghanem M.M., Takewaki T. Thymoquinone reduces hepatic glucose production in diabetic hamsters. Res. Vet. Sci. 2005, 79:219-223.
23. Dawson H.D., Li N.Q., DeCicco K.L., Nibert J.A., Ross A.C. Chronic marginal vitamin A status reduces natural killer cell number and function in aging Lewis rats. J. Nutr. 1999, 129:1510-1517.
24. Pavlovic V., Cekic S., Sokolovic D., Djindjic B. Modulatory effect of monosodium glutamate on rat thymocyte proliferation and apoptosis. Bratisl. Lek. Listy. 2006, 107:185-191.
25. Badr G., Borhis G., Treton D., Richard Y. IFN {alpha} enhances human B-cell chemotaxis by modulating ligand-induced chemokine receptor signaling and internalization. Int. Immunol. 2005, 17(4):459-467.
26. Badr G., Bédard N., Abdel Hakeem M.S., Trautmann L., Willems B., Villeneuve J.P., Haddad E.K., Sékaly R.P., Bruneau J., Shoukry N.H. Early interferon therapy for HCV rescues polyfunctional virus-specific CD8+ long-lived memory T cells. J. Virol. 2008, 82:10017-10031.
27. Hanafy M.S., Hatem M.E. Studies on the antimicrobial activity of Nigella sativa seed (black cumin). J. Ethnopharmacol. 1991, 34:275-278.
28. Zaoui A., Cherrah Y., Lacaille-Dubois M.A., Settaf A., Amarouch H., Hassar M. Diuretic and hypotensive effects of Nigella sativa in the spontaneously hypertensive rat. Therapie 2000, 55:379-382.
29. Kanter M., Meral I., Yener Z., Ozbek H., Demir H. Partial regeneration/proliferation of the beta-cells in the islets of Langerhans by Nigella sativa L. in streptozotocin-induced diabetic rats. Tohoku J. Exp. Med. 2003, 201:213-219.
30. Houghton P.J., Zarka R., de las Heras B., Hoult J.R. Fixed oil of Nigella sativa and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. Planta Med. 1995, 61:33-36.
31. Ohkawa H., Ohishi N., Yagi K. Reaction of linoleic acid hydroperoxide with thiobarbituric acid. J. Lipid Res. 1978, 19:1053-1057.
32. Pari L., Sankaranarayanan C. Beneficial effects of thymoquinone on hepatic key enzymes in streptozotocin-nicotinamide induced diabetic rats. Life Sci. 2009, 85(23-26):830-834.
33. Fararh K.M., Ibrahim A.K., Elsonosy Y.A. Thymoquinone enhances the activities of enzymes related to energy metabolism in peripheral leukocytes of diabetic rats. Res. Vet. Sci. 2010, 88(3):400-404.
34. Mabley J.G., Southan G.J., Salzman A.L., Szabó C. The combined inducible nitric oxide synthase inhibitor and free radical scavenge guanidinoethyldisulfide prevents multiple low-dose streptozotocin-induced diabetes in vivo and interleukin-1beta-induced suppression of islet insulin secretion in vitro. Pancreas 2004, 28:E39-44.
35. El-Mahmoudy A., Shimizu Y., Shiina T., Matsuyama H., El-Sayed M., Takewaki T. Successful abrogation by thymoquinone against induction of diabetes mellitus with streptozotocin via nitric oxide inhibitory mechanism. In. Immunopharmacol. 2005, 1:195-207.
36. Oliver R.C. Diabetes - a risk factor for periodontitis in adults?. J. Periodontol. 1994, 65(5):530-538.
37. Burton E.S., David J.S. Cardiovascular complications in diabetes mellitus. Curr. Opin. Pharmacol. 2005, 5:143-148.
38. Miley D.D., Terezhalmy G.T. The patient with diabetes mellitus: etiology, epidemiology, principles of medical management, oral disease burden, and principles of dental management. Quintessence Int. 2005, 36(10):779-795.
39. Thompson C.S. Animal models of diabetes mellitus: relevance to vascular complications. Curr. Pharm. Des. 2008, 14(4):309-324.
40. Lopes de Jesus C.C., Atallah A.N., Valente O., Moça Trevisani V.F. Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy. Cochrane Database Syst. Rev. 2008, 23(1):CD006695.
41. Golbidi S., Laher I. Antioxidant therapy in human endocrine disorders. Med. Sci. Monit. 2010, 16(1):RA9-24.
42. Kojo S., Tanaka K., Tokumaru S. Oxidative stress and vitamins. Nippon Rinsho. 1999, 57(10):2325-2331.
43. Salem M.L. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int. Immunopharmacol. 2005, 5(13-14):1749-1770.
44. Kapoor S. Emerging clinical and therapeutic applications of Nigella sativa in gastroenterology. World J. Gastroenterol. 2009, 15(17):2170-2171.
45. Hamdy N.M., Taha R.A. Effects of Nigella sativa oil and thymoquinone on oxidative stress and neuropathy in streptozotocin-induced diabetic rats. Pharmacology 2009, 84(3):127-134.
46. Haluzík M., Nedvídková J. The role of nitric oxide in the development of streptozotocin-induced diabetes mellitus: experimental and clinical implications. Physiol. Res. 2000, 49(Suppl. 1):S37-S42.
47. El-Mahmoudy A., Shimizu Y., Shiina T., Matsuyama H., Nikami H., Takewaki T. Macrophage-derived cytokine and nitric oxide profiles in type I and type II diabetes mellitus: effect of thymoquinone. Acta Diabetol. 2005, 42(1):23-30.
48. McLachlan K.A., O'Neal D., Jenkins A., et al. Do adiponectin, TNF alpha leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes during and after pregnancy. Diabetes Metab. Res. Rev. 2006, 22:131-138.
49. Elgazzar M.A. Thymoquinone suppresses in vitro production of IL-5 and IL-13 by mast cells in response to lipopolysaccharide stimulation. Inflamm. Res. 2007, 56(8):345-351.
50. Cheh N., Chipitsyna G., Gong Q., Yeo C.J., Arafat H.A. Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford) 2009, 11(5):373-381.
51. Han S.N., Leka L.S., Lichtenstein A.H., Ausman L.M., Meydani S.N. Effect of a therapeutic lifestyle change diet on immune functions of moderately hypercholesterolemic humans. J. Lipid Res. 2003, 44(12):2304-2310.
52. Uetrecht A.C., Bear J.E. Coronins: the return of the crown. Trends Cell Biol. 2006, 16(8):421-426.
53. Gomez T.S., Hamann M.J., McCarney S., Savoy D.N., Lubking C.M., Heldebrant M.P., Labno C.M., McKean D.J., McNiven M.A., Burkhardt J.K., Billadeau D.D. Dynamin 2 regulates T cell activation by controlling actin polymerization at the immunological synapse. Nat. Immunol. 2005, 6(3):261-270.